title: Hypotensive effects and influence on serum lipids of SQ29,852, a new angiotensin converting enzyme inhibitor, in patients with essential hypertension: a comparison with atenolol.
abstract: The effects of SQ29,852 (n = 24), a new angiotensin converting enzyme inhibitor, and atenolol (n = 22), monotherapies were compared in 46 patients with mild to moderate essential hypertension. Both SQ29,852 (mean dose 15.0 +/- 5.1 mg/day) and atenolol (mean dose 37.5 +/- 18.5 mg/day) significantly decreased both systolic and diastolic blood pressures. There were no significant changes in serum lipids, apolipoproteins, lipoproteins or atherosclerotic indices after both SQ29,852 and atenolol. There were also no significant inter-group differences. There were no serious side effects or abnormal laboratory tests in both treatment groups. It is concluded that SQ29,852 is an effective antihypertensive drug without adverse effect on lipid metabolism.
authors.affiliation: 2nd Dept. of Internal Medicine, Fukuoka University, Japan.
authors.forename: J
authors.initials: J
authors.lastname: Sasaki
authors.forename: S
authors.initials: S
authors.lastname: Koga
authors.forename: K
authors.initials: K
authors.lastname: Kato
authors.forename: M
authors.initials: M
authors.lastname: Takii
authors.forename: K
authors.initials: K
authors.lastname: Sakai
authors.forename: K
authors.initials: K
authors.lastname: Kawasaki
authors.forename: M
authors.initials: M
authors.lastname: Kagimoto
authors.forename: Y
authors.initials: Y
authors.lastname: Doi
authors.forename: K
authors.initials: K
authors.lastname: Takada
authors.forename: A
authors.initials: A
authors.lastname: Sakaue
mesh_terms: D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D001053:Apolipoproteins / Q000097:blood; D001161:Arteriosclerosis / Q000097:blood / Q000188:drug therapy; D001262:Atenolol / Q000009:adverse effects / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D008055:Lipids / Q000097:blood*; D008074:Lipoproteins / Q000097:blood; D008297:Male; D008875:Middle Aged; D009943:Organophosphorus Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D007862:Phosphatidylcholine-Sterol O-Acyltransferase / Q000097:blood; D011392:Proline / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D001053:Apolipoproteins; D008055:Lipids; D008074:Lipoproteins; D009943:Organophosphorus Compounds; D001262:Atenolol; D011392:Proline; D007862:Phosphatidylcholine-Sterol O-Acyltransferase; C054518:ceronapril